William Blair acted as the exclusive financial advisor to GenDx, a portfolio company of Ampersand Capital Partners (Ampersand), in connection with its pending sale to Eurobio Scientific (ENXTPA:ALERS) for €135 million in total consideration. The transaction was signed on August 17, 2022 and is expected to close by the end of Q3 2022.
About the Companies
Genome Diagnostics BV (GenDx) is a leader in the field of HLA typing, chimerism monitoring and related molecular diagnostic testing in the transplantation space. Established in 2005, GenDx is based in Utrecht, the Netherlands with additional presence in Chicago, USA. The company develops and markets innovative diagnostic tests, software, services, and educational products in close collaboration with renowned business partners. With more than 80 employees, the company has a dedicated team of in-house experts always striving to provide the best services for tissue-typing laboratories, scientists, and hospital specialists. GenDx’s products are distributed worldwide, either directly or by one of its HLA-specialized distributors.
Eurobio Scientific is a publicly listed entity on the Euronext Growth Paris stock exchange. The company is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology, and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The group has approximately 148 employees and three production units based in France, Germany, and in the U.S., and several affiliates based in the U.K., Switzerland, Germany, and the Netherlands.
Ampersand is a middle-market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. Ampersand is typically the first institutional investor in founder-owned businesses, where it works with entrepreneurs to help take the company to the next level. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams.
Learn more about our medical technology investment banking expertise.